Inhibition of ABCB1 and ABCG2 at the Mouse Blood−Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib

Martin Bauer; Nicolas Tournier; Oliver Langer

doi:10.1021/acs.molpharmaceut.8b01217

Inhibition of ABCB1 and ABCG2 at the Mouse Blood−Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib

Martin Bauer
, Nicolas Tournier
, Oliver Langer

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1282-1293
Number of pages	12
Journal	Molecular Pharmaceutics
DOIs	https://doi.org/10.1021/acs.molpharmaceut.8b01217
Publication status	Published - 2019

Research Field

Former Research Field - Health and Bioresources

Access to Document

10.1021/acs.molpharmaceut.8b01217Licence: Unspecified

Cite this

@article{ef5277ec39354d70abb6ad70a42d3fdc,

title = "Inhibition of ABCB1 and ABCG2 at the Mouse Blood−Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib",

author = "Martin Bauer and Nicolas Tournier and Oliver Langer",

year = "2019",

doi = "10.1021/acs.molpharmaceut.8b01217",

language = "English",

pages = "1282--1293",

journal = "Molecular Pharmaceutics",

issn = "1543-8384",

publisher = "American Chemical Society",

}

TY - JOUR

T1 - Inhibition of ABCB1 and ABCG2 at the Mouse Blood−Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib

AU - Bauer, Martin

AU - Tournier, Nicolas

AU - Langer, Oliver

PY - 2019

Y1 - 2019

U2 - 10.1021/acs.molpharmaceut.8b01217

DO - 10.1021/acs.molpharmaceut.8b01217

M3 - Article

SN - 1543-8384

SP - 1282

EP - 1293

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

ER -